论文部分内容阅读
目的探讨老年尿路感染患者中产超广谱β-内酰胺酶(ESBLs)大肠埃希菌的耐药性。方法回顾性分析2008年至2009年117例ESBLs(+)老年尿路感染患者中段尿标本结果。结果大肠埃希菌产ESBLs率自2008年的49.1%上升到2009年的53.9%。产ESBLs大肠埃希菌对氨基糖苷类,二、三代头孢菌素以及酶抑制剂抗生素的耐药性呈上升趋势。产ESBLs大肠埃希菌对第二、三代头孢菌素,氨苄西林,环丙沙星耐药率高,对头孢哌酮舒巴坦、丁胺卡那敏感,对碳青酶类无耐药。结论老年尿路感染患者中产ESBLs大肠埃希菌检出率和耐药性非常高,头孢哌酮舒巴坦是此类患者较为理想的选择。
Objective To investigate the drug resistance of extended-spectrum β-lactamases (ESBLs) Escherichia coli in elderly urinary tract infection. Methods A retrospective analysis was performed on the urine samples from 117 middle aged patients with ESBLs (+) urinary tract infection from 2008 to 2009. Results The rate of ESBLs production in Escherichia coli increased from 49.1% in 2008 to 53.9% in 2009. ESBLs-producing Escherichia coli on aminoglycosides, second and third generation cephalosporins and enzyme inhibitors antibiotics resistance is on the rise. ESBLs-producing Escherichia coli on the second and third generation cephalosporins, ampicillin, ciprofloxacin resistance rate of cefoperazone sulbactam, amikacin sensitive, no resistance to carbon blue enzymes. Conclusion The detection rate and drug resistance of ESBLs-producing Escherichia coli in elderly patients with urinary tract infection are very high. Cefoperazone sulbactam is an ideal choice for these patients.